A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

Here are the top 5 biosimilar articles for the week of April 21, 2025. Number 5: Trastuzumab biosimilars saw significant ...

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the ...

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...

To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar ...

Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy ...

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, while price-linked discounts and prescribing quotas have shown mixed or ...

A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but ...